Results 41 to 50 of about 94,073 (238)

Supplementary Figure from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

, 2021
Supplementary Figure from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative ...
John D. Crispino (15025091), Grant A. Challen (10844563), Te Ling (15118693), Sandeep Gurbuxani (732007), Ronald Hoffman (7928819), Michael Schieber (15118702), Panagiotis Ntziachristos (3618968), Marinka Bulic (15118696), Richard P. Koche (11572930), Hamza Celik (281694), Christopher A. Famulare (15021234), David E. Root (14932302), Andrew Volk (677115), Ross L. Levine (11016438), Navdeep S. Chandel (263725), Brady Stein (15021279), Praveen Suraneni (265771), Terra Lasho (15118699), Noushin Farnoud (15021231), Qiang Jeremy Wen (15017424), Ayalew Tefferi (15021276), Scott T. Younger (8819986), Christian Marinaccio (15118690), Raajit K. Rampal (15021273), Naseema Gangat (15001595)   +24 more
core   +1 more source

PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

, 2022
-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative ...
Cazzola M, Gisslinger H, Jäger R, Gisslinger B, Krauth MT, Milosevic Feenstra JD, Schischlik F, Eisenwort G, Schuster M, Bock C, Rumi E, Kralovics R, Ivanov D, Valent P., Machherndl-Spandl S, Bettelheim P, Keil F   +16 more
core   +1 more source

Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report

Biomarker Research, 2021
Background Chronic myeloid leukemia (CML) and chronic neutrophilic leukemia (CNL) are two myeloproliferative neoplasms with mutually exclusive diagnostic criteria.
Sarah A. Carratt, Diana Brewer, Julia E. Maxson, Brian J. Druker, Theodore P. Braun   +4 more
doaj   +1 more source

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis

Frontiers in Oncology, 2020
Numerous studies have documented ultrastructural abnormalities in malignant megakaryocytes from bone marrow (BM) of myelofibrosis patients but the morphology of these cells in spleen, an important extramedullary site in this disease, was not investigated
Maria Zingariello, Vittorio Rosti, Alessandro M. Vannucchi, Paola Guglielmelli, Maria Mazzarini, Giovanni Barosi, Maria Luisa Genova, Anna Rita Migliaccio, Anna Rita Migliaccio   +8 more
doaj   +1 more source

Myelodysplastic/Myeloproliferative Neoplasms [PDF]

American Journal of Clinical Pathology, 2009
AbstractMyelodysplastic/myeloproliferative neoplasms (MDS/MPNs) are rare de novo myeloid neoplasms that exhibit hybrid dysplastic and proliferative features at presentation. This SHP/EAHP Workshop session was uniquely problematic owing to the overlap between MDS/MPNs and both chronic myeloproliferative neoplasms and myelodysplasia.
openaire   +2 more sources

Myeloproliferative Neoplasm Animal Models

, 2012
Myeloproliferative neoplasm (MPN) animal models accurately re-capitulate human disease in mice and have been an important tool for the study of MPN biology and therapy.
Lane, Steven W., Brumme, Kristina, Mullally, Ann, Ebert, Benjamin L.   +3 more
core   +1 more source

The personal impact of living with a Myeloproliferative Neoplasm (MPN).

, 2023
The aim of the current study is to gain insight into the psycho-social effects of having a Myeloproliferative Neoplasm (MPN), a rare type of cancer. The impact of the disease on quality of life will be investigated, both physically, psychologically and ...
Marjan Nijkamp, Esther Bakker, catherine bolman, Lilian Lechner, Annemiek Eppingbroek   +4 more
core   +1 more source

The molecular pathogenesis of myeloproliferative neoplasms

, 2010
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of haematological stem cellmalignancies characterised by proliferation of one or more cells of the myeloid lineage.
Jones, Amy Victoria
core   +2 more sources

Breakthroughs in myeloproliferative neoplasms

Hematology, 2012
The discovery of the JAK2V617F mutation ushered the field of Philadelphia-negative myeloproliferative neoplasms (MPNs) into the era of targeted therapy. Currently, there are several JAK2 inhibitors in clinical trials for patients with MPNs, particularly for patients with myelofibrosis (MF).
Fabio P S, Santos, Srdan, Verstovsek
openaire   +2 more sources

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

Haematologica, 2010
Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in
Philip A. Beer, Christina A. Ortmann, Frank Stegelmann, Paola Guglielmelli, John T. Reilly, Thomas S. Larsen, Hans C. Hasselbalch, Alessandro M. Vannucchi, Peter Möller, Konstanze Döhner, Anthony R. Green   +10 more
doaj   +1 more source